1. A waist support frame for a detachment type waist protecting belt to hold the vertebra region of a vertebra related patient is comprised of two plastic plates, each of which has a window at the center and one guiding nut on the center of the exterior side of the inner-half of the rim, connected by two hinges, which are attached to the upper and lower parts of the plastic plates, to form a saddle like shape that fits the contour of the waist of an individual patient.
2. The waist support frame in claim 1, wherein the distances between the two plastic plates along the inner half of the rim vary along the vertical axis, depending on the contour of the individual patients back, due to the combined movement of the two hinges and the two guiding nuts.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A compound having the general formula (I):
where
n is selected from the group consisting of 0, 1 and 2;
X1 is CH, CCH3, CC\u2261N, or N;
X2 is CH or N;
R1 is absent or is selected from the group consisting of alkyl, halogen, ether, cyano, pyridyl, COCR3, CO2R4, CONH2, NO2, and CF3;
R2 is absent or represents one or more substituents selected from the group consisting of halogen, alkyl, pyridyl, cyano, acetyl, phenyl and phenyl substituted with alkyl;
R3 is selected from the group consisting of hydrogen, alkyl and CONH2; and
R4 is alkyl,
wherein at least one of R1 or R2 is present.
2. The compound of claim 1, wherein R1 is selected from the group consisting of para-nitro, para-cyanide, para-chloride, para-bromide, para-methyl, ortho-bromide, para-methyl ether, meta-trifluoromethyl, hydrogen, para-ethyl ester, para-methyl ester, para-acetyl and 3-pyridyl.
3. The compound of claim 1, wherein R2 is absent or is selected from the group consisting of para-chloride, meta-, para-dichloride, ortho-methyl, para-fluoride, para-acetyl, 2-pyridyl, ortho-cyanide, and meta-, ortho-methyl.
4. The compound of claim 1, wherein:
n=1;
R1 is selected from the group consisting of para-nitro, para-cyanide, para-bromide, para-methyl, hydrogen, para-methyl ether and para-methyl ester; and
R2 is selected from the group consisting of para-methyl, ortho-methyl and meta-methyl.
5. The compound of claim 1, wherein:
n=2;
R1 is para-methyl ester; and
R2 is absent.
6. A compound selected from the group consisting of
1-(E)-2-(4-nitrophenyl)diazen-1-yl-4-phenylpiperazine;
4-(E)-2-(4-phenylpiperazin-1-yl)diazen-1-ylbenzonitrile;
Methyl 4-(E)-2-(4-phenylpiperazin-1-yl)diazen-1-ylbenzoate;
1-{4-(E)-2-(4-phenylpiperazin-1-yl)diazen-1-ylphenyl}ethan-1-one;
1-(E)-2-(4-chlorophenyl)diazen-1-yl-4-phenylpiperazine;
1-(E)-2-(4-bromophenyl)diazen-1-yl-4-phenylpiperazine;
1-(E)-2-(4-methylphenyl)diazen-1-yl-4-phenylpiperazine;
1-(E)-2-(4-methoxyphenyl)diazen-1-yl-4-phenylpiperazine;
1-(E)-2-(2-bromophenyl)diazen-1-yl-4-phenylpiperazine;
1-(4-chlorophenyl)-4-(E)-2-(4-nitrophenyl)diazen-1-ylpiperazine;
4-(E)-2-4-(4-chlorophenyl)piperazin-1-yldiazen-1-ylbenzonitrile;
methyl 4-(E)-2-4-(4-chlorophenyl)piperazin-1-yl)diazen-1-ylbenzoate;
1-(E)-2-(4-bromophenyl)diazen-1-yl-4-(4-chlorophenyl) piperazine;
1-(4-chlorophenyl)-4-(E)-2-(4-methylphenyl)diazen-1-ylpiperazine;
1-(4-chlorophenyl)-4-(E)-2-(4-methoxyphenyl)diazen-1-ylpiperazine;
1-(3,4-dichlorophenyl)-4-(E)-2-(4-nitrophenyl)diazen-1-ylpiperazine;
4-(E)-2-4-(3,4-dichlorophenyl)piperazin-1-yldiazen-1-ylbenzonitrile;
1-(E)-2-(4-bromophenyl)diazen-1-yl-4-(3,4-dichlorophenyl)piperazine;
1-(3,4-dichlorophenyl)-4-(E)-2-(4-methylphenyl)diazen-1-ylpiperazine;
1-(3,4-dichlorophenyl)-4-(E)-2-(4-methoxyphenyl)diazen-1-ylpiperazine;
1-(3,4-dichlorophenyl)-4-(E)-2-3-(trifluoromethyl)phenyldiazen-1-ylpiperazine;
1-{4(E)-2-4-(3,4-dichlorophenyl)piperazin-1-ylphenyl}ethan-1-one;
1-(2-methylphenyl)-4-(E)-2-(4-nitrophenyl)diazen-1-ylpiperazine;
4-(E)-2-4-(2-methylphenyl)piperazin-1-yldiazen-1-ylbenzamide;
ethyl 4-(E)-2-4-methylphenyl)piperazin-1-yldiazen-1-ylbenzoate;
1-(E)-2-(4-chlorophenyl)diazen-1-yl-4-(2-methylphenyl)piperazine;
1-(E)-2-(4-methoxyphenyl)diazen-1-yl-4-(2-methylphenyl)piperazine;
1-(2-methylphenyl)-4-(E)-2-phenyldiazen-1-ylpiperazine;
1-{4-(E)-(2-methylphenyl)piperazin-1-yldiazen-1-ylphenyl}ethan-1-one;
1-(E)-2-(4-bromophenyl)diazen-1-yl-4-(4-fluorophenyl) piperazine;
1-(4-fluorophenyl)-4-(E)-2-(4-methylphenyl)diazen-1-ylpiperazine;
methyl 4-(E)-2-4(4-fluorophenyl)piperazin-1-yldiazen-1-ylbenzoate;
1-(4-{4-(E)-2-(4-bromophenyl)diazen-1-yl)piperazin-1-yl}phenyl)ethan-1-one;
1-(4-{4-(E)-2-(4-methylphenyl)diazen-1-yl)piperazin-1-yl}phenyl)ethan-1-one;
methyl 4-(E)-2-4-(4-acetylphenyl)piperazin-1-yldiazen-1-ylbenzoate;
1-(4-{4-(E)-2-(4-nitrophenyl)diazen-1-yl)piperazin-1-yl}phenyl)ethan-1-one;
4-(E)-2-4-(4-acetylphenyl)piperazin-1-yldiazen-1-ylbenzonitrile;
ethyl 4-(E)-2-4-(4-acetylphenyl)piperazin-1-yldiazen-1-ylbenzoate;
1-(4-{4-(E)-2-phenyldiazen-1-ylpiperazin-1-yl}phenyl)ethan-1-one;
1-(E)-2-(4-nitrophenyl)diazen-1-yl-4-(pyridine-2-yl)piperazine;
4-(E)-2-pyridin-2-yl)piperazin-1-yldiazen-1-ylbenzonitrile;
methyl 4-(E)-2-4-(pyridin-2-yl)piperazin-1-yldiazen-1-ylbenzoate;
1-(E)-2-(4-bromophenyl)diazen-1-yl-4-(pyridin-2-yl)piperazine;
1-(E)-2-(4-methylphenyl)diazen-1-yl-4-(pyridin-2-yl)piperazine;
1-{2-(E)-4-pyridine-2-yl)piperazine-1-yldiazen-1-ylphenyl}ethan-1-one;
1-(E)-2-(2-bromophenyl)diazen-1-yl-4-(pyridin-2-yl)piperazine;
1-(E)-2-(3-pyridyl)diazen-1-yl-4-(pyridin-2-yl)piperazine;
1-(E)-2-phenyldiazen-1-yl-4-(pyridin-2-yl)piperazine;
2-{4-(E)-2-(4-bromophenyl)diazen-1-ylpiperazin-1-yl}benzonitrile;
2-{4-(E)-2-(4-methylphenyl)diazen-1-ylpiperazin-1-yl}benzonitrile;
methyl 4-(E)-2-4-(2-cyanophenyl)piperazin-1-yldiazen-1-ylbenzoate;
2-{4-(E)-2-(4-methoxyphenyl)diazen-1-ylpiperazin-1-yl}benzonitrile;
1-(2,3-dimethylphenyl)-4-(E)-2-(4-nitrophenyl)diazen-1-ylpiperazine
4-(E)-2-4-(2,3-dimethylphenyl)piperazin-1-yldiazen-1-ylbenzonitrile;
methyl 4-(E)-2-4-(2,3-dimethylphenyl) piperazin-1-yldiazen-1-ylbenzoate;
1-(E)-2-(4-bromophenyl)diazen-1-yl-4-(2,3-dimethylphenyl) piperazine;
1-(2,3-dimethylphenyl)-4-(E)-2-(4-methylphenyl)diazen-1-ylpiperazine;
1-(2,3-dimethylphenyl)-4-(E)-2-phenyldiazen-1-ylpiperazine;
1-(E)-2-(4-chlorophenyl)diazen-1-yl-4-(2,3-dimethylphenyl) piperazine;
1-(2,3-dimethylphenyl)-4-(E)-2-(4-methoxyphenyl)diazen-1-ylpiperazine;
1-(4-methylphenyl)methyl-4-(E)-2-(4-nitrophenyl)diazen-1-ylpiperazine;
4-(E)-2-{4-(4-methylphenyl)methylpiperazin-1-yl}diazen-1-ylbenzonitrile;
methyl 4-(E)-2-{4-(4-methylphenyl)methylpiperazin-1-yl}diazen-1-ylbenzoate;
1-(E)-2-(4-bromophenyl)diazen-1-yl-4-(4-methylphenyl)methylpiperazine;
1-(E)-2-(4-methylphenyl)diazen-1-yl-4-(4-methylphenyl)methylpiperazine;
1-(4-methylphenyl)methyl-4-(E)-2-phenyldiazen-1-ylpiperazine;
1-(3-methylphenyl)methyl-4-(E)-2-(4-nitrophenyl)diazen-1-ylpiperazine;
4-(E)-2-{4-(3-methylphenyl)methylpiperazin-1-yl}diazen-1-ylbenzonitrile;
methyl 4-(E)-2-{4-(3-methylphenyl)methylpiperazin-1-yl}diazen-1-ylbenzoate;
1-(E)-2-(4-bromophenyl)diazen-1-yl-4-(3-methylphenyl)methylpiperazine;
1-(E)-2-(4-methylphenyl)diazen-1-yl-4-(3-methylphenyl)methylpiperazine;
1-(2-methylphenyl)methyl-4-(E)-2-(4-nitrophenyl)diazen-1-ylpiperazine;
4-(E)-2-{4-(2-methylphenyl)methylpiperazin-1-yl}diazen-1-ylbenzonitrile;
methyl 4-(E)-2-{4-(2-methylphenyl)methylpiperazin-1-yl}diazen-1-ylbenzoate;
1-(E)-2-(4-bromophenyl)diazen-1-yl-4(2-methylphenyl)methylpiperazine;
1-(E)-2-(4-methylphenyl)diazen-1-yl-4-(2-methylphenyl)methylpiperazine;
1-(2-methylphenyl)methyl-4-(E)-2-phenyldiazen-1-yl-4-piperazine; and
methyl 4-(E)-2-4-(2-phenylethyl)piperazin-1-yldiazen-1-ylbenzoate.
7. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
8. The compound of claim 6, wherein the compound is 4-(E)-2-(4-phenylpiperazin-1-yl)diazen-1-ylbenzonitrile.
9. The compound of claim 6, wherein the compound is methyl 4-(E)-2-(4-phenylpiperazin-1-yl)diazen-1-ylbenzoate.
10. The compound of claim 6, wherein the compound is 1-(E)-2-(4-methylphenyl)diazen-1-yl-4-phenylpiperazine.
11. The compound of claim 6, wherein the compound is 1-(E)-2-(4-nitrophenyl)diazen-1-yl-4-phenylpiperazine.